Global Blood Screening Market Size study & Forecast, by Technology (Nucleic Acid Amplification Test, ELISA, Western Blotting), by Product (Reagent, Instrument) and Regional Forecasts 2025-2035

Description

The Global Blood Screening Market, valued at approximately USD 3.4 billion in 2024, is projected to expand at a compelling CAGR of 11.90% from 2025 to 2035. Blood screening, an indispensable process in modern healthcare systems, plays a pivotal role in detecting infectious agents and safeguarding patients from transfusion-transmissible infections. It involves the use of highly sophisticated testing technologies that ensure donated blood is free from pathogens such as HIV, hepatitis viruses, and syphilis. The market's momentum is being propelled by the escalating demand for safe blood transfusions, driven by the rising incidence of chronic diseases, surgical interventions, and trauma-related procedures worldwide. Furthermore, the expansion of healthcare infrastructure in emerging economies and government-led initiatives to enforce mandatory blood testing are adding to the sector's upward trajectory.

Over the past decade, the pace of innovation in blood screening technology has intensified, enabling healthcare providers to achieve higher sensitivity and specificity in their testing protocols. Techniques such as Nucleic Acid Amplification Testing (NAT) have emerged as game-changers, drastically reducing the diagnostic window for infectious agents and minimizing the risk of transmission. According to WHO data, the demand for blood components continues to surge in line with the aging global population and increasing prevalence of diseases that necessitate transfusions. However, the industry is not without challenges. The high cost of advanced screening instruments, coupled with stringent regulatory frameworks, can hinder rapid adoption, especially in low-resource settings. Nevertheless, with the integration of automation, AI-driven diagnostic platforms, and the expansion of private-public healthcare partnerships, lucrative opportunities are on the horizon for both established players and new entrants.

From a geographical perspective, North America held a dominant market share in 2025, fueled by its robust healthcare system, high awareness about transfusion safety, and early adoption of cutting-edge diagnostics. The presence of key market players and favorable reimbursement policies have further fortified the region's leadership position. Europe closely follows, supported by stringent regulatory mandates, well-established blood banks, and advanced laboratory capabilities. Meanwhile, the Asia Pacific region is projected to record the fastest growth during the forecast period, driven by a surge in healthcare investments, rising blood donation rates, and the growing burden of infectious diseases in countries like India and China. Government campaigns to improve blood safety standards, along with investments in modernizing diagnostic laboratories, are expected to amplify the market's expansion in this region. Latin America and the Middle East & Africa are also showing steady growth, albeit at a slower pace, as infrastructure improvements and awareness campaigns begin to take root.

Major market players included in this report are:

Hoffmann-La Roche Ltd.
Abbott Laboratories
Bio-Rad Laboratories, Inc.
Grifols, S.A.
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Ortho Clinical Diagnostics
Becton, Dickinson and Company
Beckman Coulter, Inc.
QIAGEN N.V.
Danaher Corporation
Merck KGaA
PerkinElmer Inc.
Biomerieux SA
Agilent Technologies, Inc.

Global Blood Screening Market Report Scope:

Historical Data - 2023, 2024
Base Year for Estimation - 2024
Forecast period - 2025-2035
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below:

By Technology:

Nucleic Acid Amplification Test
ELISA
Western Blotting

By Product:

Reagent
Instrument

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
South Africa
Rest of Middle East & Africa

Key Takeaways:

Market Estimates & Forecast for 10 years from 2025 to 2035.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Blood Screening Market Report Scope & Methodology

1.1. Research Objective
1.2. Research Methodology
- 1.2.1. Forecast Model
- 1.2.2. Desk Research
- 1.2.3. Top Down and Bottom-Up Approach
1.3. Research Attributes
1.4. Scope of the Study
- 1.4.1. Market Definition
- 1.4.2. Market Segmentation
1.5. Research Assumption
- 1.5.1. Inclusion & Exclusion
- 1.5.2. Limitations
- 1.5.3. Years Considered for the Study

Chapter 2. Executive Summary

2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. Key Findings

Chapter 3. Global Blood Screening Market Forces Analysis

3.1. Market Forces Shaping The Global Blood Screening Market (2024-2035)
3.2. Drivers
- 3.2.1. Rising Demand for Safe Blood Transfusions Due to Chronic Diseases & Trauma
- 3.2.2. Expansion of Healthcare Infrastructure and Government Initiatives
3.3. Restraints
- 3.3.1. High Cost of Advanced Screening Instruments
- 3.3.2. Stringent Regulatory Frameworks Impacting Adoption
3.4. Opportunities
- 3.4.1. Integration of Automation and AI-Driven Diagnostic Platforms
- 3.4.2. Growth in Emerging Economies and Private-Public Healthcare Partnerships

Chapter 4. Global Blood Screening Industry Analysis

4.1. Porter's 5 Forces Model
- 4.1.1. Bargaining Power of Buyer
- 4.1.2. Bargaining Power of Supplier
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. Porter's 5 Force Forecast Model (2024-2035)
4.3. PESTEL Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
4.4. Top Investment Opportunities
4.5. Top Winning Strategies (2025)
4.6. Market Share Analysis (2024-2025)
4.7. Global Pricing Analysis And Trends 2025
4.8. Analyst Recommendation & Conclusion

Chapter 5. Global Blood Screening Market Size & Forecasts by Technology 2025-2035

5.1. Market Overview
5.2. Nucleic Acid Amplification Test (NAT)
- 5.2.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.2.2. Market Size Analysis, by Region, 2025-2035
5.3. ELISA
- 5.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.3.2. Market Size Analysis, by Region, 2025-2035
5.4. Western Blotting
- 5.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.4.2. Market Size Analysis, by Region, 2025-2035

Chapter 6. Global Blood Screening Market Size & Forecasts by Product 2025-2035

6.1. Market Overview
6.2. Reagent
- 6.2.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.2.2. Market Size Analysis, by Region, 2025-2035
6.3. Instrument
- 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.3.2. Market Size Analysis, by Region, 2025-2035

Chapter 7. Global Blood Screening Market Size & Forecasts by Region 2025-2035

7.1. Blood Screening Market, Regional Market Snapshot
7.2. Top Leading & Emerging Countries
7.3. North America Blood Screening Market
- 7.3.1. U.S. Blood Screening Market
  - 7.3.1.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.3.1.2. Product Breakdown Size & Forecasts, 2025-2035
- 7.3.2. Canada Blood Screening Market
  - 7.3.2.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.3.2.2. Product Breakdown Size & Forecasts, 2025-2035
7.4. Europe Blood Screening Market
- 7.4.1. UK Blood Screening Market
  - 7.4.1.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.4.1.2. Product Breakdown Size & Forecasts, 2025-2035
- 7.4.2. Germany Blood Screening Market
  - 7.4.2.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.4.2.2. Product Breakdown Size & Forecasts, 2025-2035
- 7.4.3. France Blood Screening Market
  - 7.4.3.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.4.3.2. Product Breakdown Size & Forecasts, 2025-2035
- 7.4.4. Spain Blood Screening Market
  - 7.4.4.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.4.4.2. Product Breakdown Size & Forecasts, 2025-2035
- 7.4.5. Italy Blood Screening Market
  - 7.4.5.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.4.5.2. Product Breakdown Size & Forecasts, 2025-2035
- 7.4.6. Rest of Europe Blood Screening Market
  - 7.4.6.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.4.6.2. Product Breakdown Size & Forecasts, 2025-2035
7.5. Asia Pacific Blood Screening Market
- 7.5.1. China Blood Screening Market
  - 7.5.1.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.5.1.2. Product Breakdown Size & Forecasts, 2025-2035
- 7.5.2. India Blood Screening Market
  - 7.5.2.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.5.2.2. Product Breakdown Size & Forecasts, 2025-2035
- 7.5.3. Japan Blood Screening Market
  - 7.5.3.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.5.3.2. Product Breakdown Size & Forecasts, 2025-2035
- 7.5.4. Australia Blood Screening Market
  - 7.5.4.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.5.4.2. Product Breakdown Size & Forecasts, 2025-2035
- 7.5.5. South Korea Blood Screening Market
  - 7.5.5.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.5.5.2. Product Breakdown Size & Forecasts, 2025-2035
- 7.5.6. Rest of APAC Blood Screening Market
  - 7.5.6.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.5.6.2. Product Breakdown Size & Forecasts, 2025-2035
7.6. Latin America Blood Screening Market
- 7.6.1. Brazil Blood Screening Market
  - 7.6.1.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.6.1.2. Product Breakdown Size & Forecasts, 2025-2035
- 7.6.2. Mexico Blood Screening Market
  - 7.6.2.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.6.2.2. Product Breakdown Size & Forecasts, 2025-2035
7.7. Middle East and Africa Blood Screening Market
- 7.7.1. UAE Blood Screening Market
  - 7.7.1.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.7.1.2. Product Breakdown Size & Forecasts, 2025-2035
- 7.7.2. Saudi Arabia (KSA) Blood Screening Market
  - 7.7.2.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.7.2.2. Product Breakdown Size & Forecasts, 2025-2035
- 7.7.3. South Africa Blood Screening Market
  - 7.7.3.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.7.3.2. Product Breakdown Size & Forecasts, 2025-2035
- 7.7.4. Rest of Middle East & Africa Blood Screening Market
  - 7.7.4.1. Technology Breakdown Size & Forecasts, 2025-2035
  - 7.7.4.2. Product Breakdown Size & Forecasts, 2025-2035

Chapter 8. Competitive Intelligence

8.1. Top Market Strategies
8.2. Hoffmann-La Roche Ltd.
- 8.2.1. Company Overview
- 8.2.2. Key Executives
- 8.2.3. Company Snapshot
- 8.2.4. Financial Performance (Subject to Data Availability)
- 8.2.5. Product/Services Port
- 8.2.6. Recent Development
- 8.2.7. Market Strategies
- 8.2.8. SWOT Analysis
8.3. Abbott Laboratories
8.4. Bio-Rad Laboratories, Inc.
8.5. Grifols, S.A.
8.6. Siemens Healthineers AG
8.7. Thermo Fisher Scientific Inc.
8.8. Ortho Clinical Diagnostics
8.9. Becton, Dickinson and Company
8.10. Beckman Coulter, Inc.
8.11. QIAGEN N.V.
8.12. Danaher Corporation
8.13. Merck KGaA
8.14. PerkinElmer Inc.
8.15. Biomerieux SA
8.16. Agilent Technologies, Inc.